BMO Capital sets a $518 price target for ISRG, citing early-stage da Vinci 5 upgrade cycle and broadening procedure growth.
BMO Capital initiated coverage of Intuitive Surgical (NASDAQ:ISRG) with an Outperform rating and a $518 price target on July 9, 2026. Analyst Vik Chopra highlighted the early innings of the da Vinci 5 upgrade cycle, expanding procedure growth into new specialties and geographies, and a durable earnings stream.
Recent analyst actions include Evercore ISI lowering its price target to $430 from $480 on July 6, while maintaining an In Line rating. BofA’s Travis Steed reduced ISRG’s target to $515 from $520 last month, citing lower utilization and inflation headwinds for 2027.
Intuitive Surgical develops and markets products aimed at enhancing healthcare quality, with a focus on robotic-assisted surgical systems.